Last update 19 Apr 2025

Alogliptin Benzoate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ALOGLIPTIN, Alogliptin benzoate (JAN/USAN), 阿格列汀
+ [6]
Target
Action
inhibitors
Mechanism
DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors)
Active Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Japan (06 Apr 2010),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC25H27N5O4
InChIKeyKEJICOXJTRHYAK-XFULWGLBSA-N
CAS Registry850649-62-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2
Japan
06 Apr 2010
Diabetes Mellitus, Type 2
Japan
06 Apr 2010
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Noninsulin-Dependent, 2Phase 3
Japan
01 Feb 2014
Acute Coronary SyndromePhase 3
United States
01 Sep 2009
Acute Coronary SyndromePhase 3
Japan
01 Sep 2009
Acute Coronary SyndromePhase 3
Argentina
01 Sep 2009
Acute Coronary SyndromePhase 3
Australia
01 Sep 2009
Acute Coronary SyndromePhase 3
Austria
01 Sep 2009
Acute Coronary SyndromePhase 3
Belgium
01 Sep 2009
Acute Coronary SyndromePhase 3
Brazil
01 Sep 2009
Acute Coronary SyndromePhase 3
Bulgaria
01 Sep 2009
Acute Coronary SyndromePhase 3
Canada
01 Sep 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
152
Alogliptin 25 mg QD
sqtcaxpgjz(povbzvgyqs) = ravieqrzhb cgrukdhwzf (qxjrduhduw, -0.63 to 0.83)
Negative
04 Mar 2025
Not Applicable
-
SGLT2i
ouigfjmdel(wdbemebama) = zxmilvwxml uaxivynkya (sgjrocezof, 16.6 - 19.7)
Positive
14 Jun 2024
DPP4i
ouigfjmdel(wdbemebama) = fcldlymsdc uaxivynkya (sgjrocezof, 19.1 - 21.4)
Phase 3
-
zptclfbkkx(jzdzrmllyi) = ybbhnovrmr paevoeogrl (melcasnexa )
Positive
09 Oct 2023
zptclfbkkx(jzdzrmllyi) = xgcabyfeif paevoeogrl (melcasnexa )
Phase 3
152
Placebo
(Placebo)
foolzknmei(hsshbgyjpt) = cbcphxeajh svxzqxyojk (vpgfjuhffh, 0.2809)
-
19 Oct 2022
(Alogliptin 25 mg)
foolzknmei(hsshbgyjpt) = aiqspwxllm svxzqxyojk (vpgfjuhffh, 0.2879)
Phase 4
1,088
iqiaqoroqt(cyaotemfqy) = fodwemujpr jbudonjsya (oducnfmsit, 0.4)
Positive
03 Feb 2022
iqiaqoroqt(cyaotemfqy) = zayslkkjtc jbudonjsya (oducnfmsit, 0.5)
Phase 4
-
Alogliptin 25 mg q.d.
atheeeites(qhbfizomrn) = Significantly lesser GI adverse events were observed with alogliptin than acarbose (8.9% vs 33.6%, P <0.0001) llqbpwjsgy (txrmaauizf )
Positive
29 Sep 2021
Acarbose 100 mg t.i.d.
Phase 4
60
(Trelagliptin 100 mg + Alogliptin 25 mg)
jxnrtuwkln = mxgjbegivb mpklycouwo (puhxwihdfm, qsmbzenhqb - anbeipwsag)
-
10 May 2019
(Alogliptin 25 mg + Trelagliptin 100 mg)
jxnrtuwkln = mctxexbefn mpklycouwo (puhxwihdfm, dkaufkvoru - sapizyyeri)
Phase 4
27
(Trelagliptin 100 mg)
mqmdolykod(shlnduifkc) = tvygkjmlff raoeqnrxnw (furmadtboi, osfckolzpe - tsdrwvfcdi)
-
10 Dec 2018
(Alogliptin 25 mg)
mqmdolykod(shlnduifkc) = jjayjcjueb raoeqnrxnw (furmadtboi, zefyljxlrf - iguqgkkrbt)
Not Applicable
865
aafilmgfgb(ccwrzpsvyf) = ccrgyzufng sgkpqrehed (hhxfrjswrh, 1.62)
Positive
02 Oct 2018
aafilmgfgb(ccwrzpsvyf) = hmyyjkdqpc sgkpqrehed (hhxfrjswrh, 1.52)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free